Sinclair Dunlop, Managing Partner
Mr. Dunlop has twenty years of experience successfully partnering new technologies with and delivering competitive returns to international investors. Prior to co-founding Rock Spring Ventures, Mr. Dunlop successfully raised MASA Life Science Ventures, LP (“MLSV” – www.mlsvfund.com). MLSV’s investors include several leading institutions and corporations in Japan and Korea, including a ‘top-ten’ Japanese Pharmaceutical company, the largest distributor of cardiac-health medical devices in Japan, a global financial institution and one of Japan’s leading publicly-traded Biotechnology companies. Mr. Dunlop’s international network of blue-chip co-investors, his experienced management team and a Scientific Advisory Board of renowned experts successfully built and managed a portfolio of leading life science companies. As Managing Partner of MLSV, he currently serves on the Board of Directors of Maxcyte Inc. and Apellis Pharmaceuticals Inc. He holds an M.B.A. from Columbia Business School, an M.A. (Honours) in Political Economy from Glasgow University, and a M.A. in International Relations from Syracuse University.
Kyparissia Sirinakis, Managing Partner
Ms. Sirinakis has more than twenty years of experience and a strong track record as an early-stage investor and senior executive in various health science and technology companies. Prior to co-founding Rock Spring Ventures, Ms. Sirinakis was a senior member of the MLSV management team where she actively managed several MLSV portfolio companies. Ms. Sirinakis was the Founder and Managing Director of WomenAngels.net LLC (“WAN”), a successful early-stage venture focused on the U.S. Mid-Atlantic region. WAN, a fund launched in 2000, generated a highly competitive Internal Rate of Return. WAN's success was driven by investing in highly disruptive technology platforms developed by strong management teams targeting large and unmet market needs. Ms. Sirinakis also has extensive experience working in the university environment as the Director of a technology accelerator and adjunct professor at George Mason University. She was the CFO for Oncologix, a Maryland venture-backed, early-stage biotechnology company which was subsequently sold to Antigenics, Inc. Ms. Sirinakis has held positions on the Board of Directors for numerous start-up companies throughout her career. She is a graduate of Boston College’s School of Management Honours Program and a Certified Public Accountant in the State of Maryland.
Rock Spring Ventures UK Team:
Mary Canning, Ph.D., Associate
Ms. Canning is a molecular biologist with extensive experience in the commercialisation of early-stage health science technologies. As a Business Manager with Medical Research Council Technology (MRCT) she was responsible for exploitation of intellectual property arising from a number of MRC Units. She has previously worked with the Scottish Enterprise Proof of Concept Programme, building and funding spin-out companies from leading Scottish academic institutions. Dr. Canning was a Medici Fellow at the University of Nottingham where she participated in a fellowship in entrepreneurship for scientists. Dr. Canning has a Ph.D. in molecular biology from the University of Edinburgh. Dr. Canning will lead RSV’s UK office’s diligence efforts.
David Farquhar, Venture Partner
Mr. Farquhar is a transaction-oriented serial entrepreneur with a track record of delivering shareholder value through international growth. In the past 20 years he has founded or invested in a dozen start-ups in the enterprise software and technology sectors with a significant emphasis on building global sales channels. As a founder/CEO, angel investor and business mentor, Mr. Farquhar has been integral in multiple fundraising, acquisition and trade sale transactions in Europe, North America and Asia. He is the founder of Northface Ventures and is an advisor to Tomorrow Ventures LLC. He is also Chairman of two software companies, SeeByte and Stipso, as well as the Advisory Board of the School of Computing at the University of Dundee.
Rock Spring Ventures US Team:
C. Wyatt Somogyi, Associate
Mr. Somogyi joined RSV’s US office in 2012 as an intern while completing his M.S. in Biotechnology from Georgetown University. Mr. Somogyi focuses on conducting due diligence on early-stage investment and partnership candidates for RSV’s strategic investors. Mr. Somogyi graduated magna cum laude from Connecticut College with a degree in Biochemistry, Cellular, and Molecular Biology. While earning his BS degree he focused on organic chemistry, researching a novel synthesis of a cyclooctanoid polycyclic ring system. Mr. Somogyi is also a graduate of the Bridge Program at the Tuck School of Business at Dartmouth College.
Ken Carter, Ph.D., Venture Partner
Dr. Carter has been involved in the formation and early stage development of several biotechnology companies as a co-founder, consultant or member of the board of directors. He co-founded Avalon Pharmaceuticals, Inc. in January 1999 and served as CEO for 10 years until 2009 when Avalon merged with Clinical Data, Inc. Prior to founding Avalon, Dr. Carter directed the gene mapping initiative at Human Genome Sciences, Inc. where he worked for several years and played a role in the discovery, cloning, and chromosomal mapping of dozens of novel human genes. Dr. Carter has served on the boards of directors for multiple biotechnology industry organizations including the Maryland Health Care Product Development Corporation and the National BIO Industry Organization. He also served recently as a special advisor to the Maryland Governor's Life Sciences Advisory Board and is on the Advisory Council for the Center for Biotechnology Education at Johns Hopkins University where he also holds an adjunct faculty appointment.
Steve Dubin, Venture Partner
Mr. Dubin has deep experience as a venture capitalist and senior executive in public and private companies with an emphasis on corporate development, business acquisition, customer relations, growth strategies and corporate finance. Mr. Dubin is currently a Senior Advisor to DSM Nutritional Products (Basel, Switzerland) advising DSM Nutritional Products on mergers, acquisitions and other corporate business opportunities. Mr. Dubin served as Chief Executive Officer of Martek Biosciences Corporation (NASDAQ: MATK) from July 2006 until October 2011 when it was acquired by DSM. Mr. Dubin played a key role in developing Martek's business from an R&D company to a fully integrated, profitable, commercial organization with over $470 million in annual sales. He served in a variety of positions with Martek over the 14 years before his election as CEO. Mr. Dubin's other experience includes working with and financing a variety of early-stage technology companies and spending 12 years in various positions at Suburban Bank, now part of Bank of America, including Vice President and Treasurer of its venture capital subsidiary, Suburban Capital Corporation. Mr. Dubin also co-founded, in 2001, the Chesapeake Emerging Opportunities Club, LLC, an angel investing fund based in Columbia, MD. He graduated from the University of Maryland, College Park in 1974; received his Juris Doctor Degree in 1980 from the National Law Center at the George Washington University. Mr. Dubin currently chairs the Maryland Economic Development Commission, having been appointed to that role by Governor Martin O'Malley. He is also a member of the Board of Visitors of the University of Maryland's A. James Clark School of Engineering and a member of the Intellectual Property Advisory Board of the George Washington University Law School.
Erika Smith, Venture Advisor
Ms. Smith has over twenty years of business management and technical experience within the life science industry spanning the fields of pharmaceuticals, medical devices and diagnostics. She has worked with leading companies such as Boston Scientific (NYSE: BSE), Respironics (NASDAQ: RESP) and IVAX (AMEX: IPI) and held key positions in product development, quality assurance/ regulatory affairs, marketing, and business development. She has extensive experience in developing business and marketing strategies for emerging technologies and established product lines. At Rock Spring Ventures she is responsible for sourcing, performing due diligence and supporting closure on investments. Ms. Smith teaches at the National Institutes of Health and has been a recognized guest speaker at Georgetown University's Masters of Biotechnology program and at Virginia Tech. She sits on the advisory board for a number of emerging life-science companies. Ms. Smith received both a BE in Biomedical and Electrical Engineering as well as an MBA from Vanderbilt University.
Isao Kikuchi, Managing Director, RSV Japan
Mr. Kikuchi manages RSV's Japan office in Tokyo. Mr. Kikuchi has held senior international executive management roles at leading multinational corporations in Asia, Eastern Europe and the Middle East. His areas of expertise include new technologies, finance, large-scale project development and alternative energy. Mr. Kikuchi majored in Economics at the Hitotsubashi University in Tokyo, Japan.
Samuel Lee, Managing Director, RSV Korea
Mr. Lee manages RSV's Korea office in Seoul. Mr. Lee brings over 15 years of experience in venture investments and building early-stage companies in the U.S., Asia and Israel across multiple sectors including healthcare IT. He has extensive cross-border business development and venture investing experience. Mr. Lee holds M.S. and B.S. degrees in Electrical Engineering from Columbia University.